Ascendis Pharma A/S

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell ASND and other ETFs, options, and stocks.

About ASND

Ascendis Pharma A/S is a biopharmaceutical company, which engages in the development of drug candidates. It specializes in its TransCon technologies to develop new therapies that address unmet medical needs. 

CEO
Jan Møller Mikkelsen
CEOJan Møller Mikkelsen
Employees
Employees
Headquarters
Hellerup, Capital Region
HeadquartersHellerup, Capital Region
Founded
2006
Founded2006
Employees
Employees

ASND Key Statistics

Market cap
15.76B
Market cap15.76B
Price-Earnings ratio
19.10
Price-Earnings ratio19.10
Dividend yield
Dividend yield
Average volume
825.03K
Average volume825.03K
High today
$261.68
High today$261.68
Low today
$228.56
Low today$228.56
Open price
$256.25
Open price$256.25
Volume
2.95M
Volume2.95M
52 Week high
$282.15
52 Week high$282.15
52 Week low
$186.05
52 Week low$186.05

Stock Snapshot

Ascendis Pharma A/S(ASND) stock is priced at $239.77, giving the company a market capitalization of 15.76B. It carries a P/E multiple of 19.10.

On 2026-09-16, Ascendis Pharma A/S(ASND) stock moved within a range of $228.56 to $261.68. With shares now at $239.77, the stock is trading +4.9% above its intraday low and -8.4% below the session's peak.

Trading volume for Ascendis Pharma A/S(ASND) stock has reached 2.95M, versus its average volume of 825.03K.

Over the past 52 weeks, Ascendis Pharma A/S(ASND) stock has traded between a high of $282.15 and a low of $186.05.

Over the past 52 weeks, Ascendis Pharma A/S(ASND) stock has traded between a high of $282.15 and a low of $186.05.

ASND News

Simply Wall St 40m
Ascendis Pharma Reclaims Global TransCon Rights For Obesity And Heart Disease - simplywall.st

...

Ascendis Pharma Reclaims Global TransCon Rights For Obesity And Heart Disease - simplywall.st
TipRanks 17h
Ascendis Pharma falls -12.8%

Ascendis Pharma (ASND) is down -12.8%, or -$33.92 to $231.00. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial n...

TipRanks 23h
Ascendis Pharma Unveils $400 Million Share Repurchase Program

An announcement from Ascendis Pharma ( (ASND) ) is now available. On September 14, 2026, Ascendis Pharma announced that its board had authorized a share repurc...

Analyst ratings

100%

of 22 ratings
Buy
100%
Hold
0%
Sell
0%

More ASND News

Benzinga 6d
Ascendis Pharma Says Growth Drug Shows Benefits in Infants

Ascendis Pharma A/S (NASDAQ:ASND) on Wednesday announced Week 52 data from the open-label sentinel cohort of its reACHin trial. The data showed that once-weekl...

Ascendis Pharma Says Growth Drug Shows Benefits in Infants
TipRanks 6d
Top Ascendis Pharma Executive Makes Bold Move With Major Stock Sale

New insider activity at Ascendis Pharma ( (ASND) ) has taken place on September 9, 2026. Ascendis Pharma’s Senior Vice President & Principal Accounting Officer,...

TipRanks 7d
Ascendis Pharma announces data from reACHin Trial

Ascendis Pharma (ASND) announced Week 52 data from the open-label sentinel cohort portion of the reACHin Trial showing that treatment with once-weekly TransCon...

People also own

Based on the portfolios of people who own ASND. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.